Biocon Limited has informed the Exchange regarding a press release dated December 23, 2021, titled "Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGIApproval".
Biocon Limited has informed the Exchange regarding a press release dated December 23, 2021, titled "Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGIApproval".